Patents by Inventor Tina Weinzierl

Tina Weinzierl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MONOCLONAL ANTIBODIES AGAINST BCMA
    Publication number: 20230322957
    Abstract: The invention relates to new antibodies against BCMA, their manufacture and use.
    Type: Application
    Filed: November 21, 2022
    Publication date: October 12, 2023
    Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Camille Delon, Lydia Jasmin Hanisch, Anne Freimoser-Grundschober, Christian Klein, Ekkehard Moessner, Samuel Moser, Pablo Umana, Tina Weinzierl
  • Antibodies binding to STEAP-1
    Patent number: 11685790
    Abstract: The present invention generally relates to antibodies that bind to STEAP-1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: August 11, 2021
    Date of Patent: June 27, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Thomas Hofer, Maximiliane Koenig, Ekkehard Moessner, Jens Niewoehner, Tina Weinzierl, Laurent Lariviere
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20230076791
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: May 25, 2022
    Publication date: March 9, 2023
    Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane NEUMANN, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
  • Bispecific T cell activating antigen binding molecules
    Patent number: 11459404
    Abstract: The present invention generally relates to bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: October 4, 2022
    Assignee: Roche Glycart AG
    Inventors: Marina Bacac, Peter Bruenker, Christiane Neumann, Christian Klein, Ekkehard Moessner, Pablo Umana, Tina Weinzierl
  • T CELL ACTIVATING BISPECIFIC ANTIGEN BINDING MOLECULES
    Publication number: 20220220224
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target 511cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: January 20, 2022
    Publication date: July 14, 2022
    Inventors: Marina BACAC, Peter BRUENKER, Anne FREIMOSER-GRUNDSCHOBER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20220064296
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: November 12, 2021
    Publication date: March 3, 2022
    Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane NEUMANN, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
  • ANTIBODIES BINDING TO STEAP-1
    Publication number: 20220041747
    Abstract: The present invention generally relates to antibodies that bind to STEAP-1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: August 11, 2021
    Publication date: February 10, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Thomas HOFER, Maximiliane KOENIG, Ekkehard MOESSNER, Jens NIEWOEHNER, Tina WEINZIERL, Laurent LARIVIERE
  • Antibodies binding to STEAP-1
    Patent number: 11180571
    Abstract: The present invention generally relates to antibodies that bind to STEAP-1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: November 23, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Thomas Hofer, Maximiliane Koenig, Ekkehard Moessner, Jens Niewoehner, Tina Weinzierl, Laurent Lariviere
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20210253703
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: May 3, 2021
    Publication date: August 19, 2021
    Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane NEUMANN, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20210253704
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: May 3, 2021
    Publication date: August 19, 2021
    Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane JAEGER, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
  • Antibodies binding to HLA-A2/MAGE-A4
    Publication number: 20210230278
    Abstract: The present invention generally relates to antibodies that bind to HLA-A2/MAGE-A4, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: December 17, 2020
    Publication date: July 29, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Tina Weinzierl, Lydia Jasmin Hanisch, Alexander Bujotzek, Alejandro Carpy Gutierrez Cirlos, Stefan Klostermann, Christian Klein, Simon Patrick Keiser, Tanja Fauti, Estelle Marrer-Berger, Pablo Umaña
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20210101979
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: December 18, 2020
    Publication date: April 8, 2021
    Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane NEUMANN, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20200385470
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: August 18, 2020
    Publication date: December 10, 2020
    Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane JAEGER, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
  • Bispecific T cell activating antigen binding molecules
    Patent number: 10781257
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: September 22, 2020
    Assignee: Roche Glyeart AG
    Inventors: Marina Bacac, Thomas Hofer, Ralf Hosse, Christiane Neumann, Christian Klein, Ekkehard Moessner, Pablo Umana, Tina Weinzierl
  • Bispecific T cell activating antigen binding molecules
    Patent number: 10781258
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: September 22, 2020
    Assignee: Roche Glycart AG
    Inventors: Marina Bacac, Thomas Hofer, Ralf Hosse, Christiane Neumann, Christian Klein, Ekkehard Moessner, Pablo Umana, Tina Weinzierl
  • MONOCLONAL ANTIBODIES AGAINST BCMA
    Publication number: 20200283545
    Abstract: The invention relates to new antibodies against BCMA, their manufacture and use.
    Type: Application
    Filed: March 17, 2020
    Publication date: September 10, 2020
    Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Camille Delon, Lydia Jasmin Hanisch, Anne Freimoser-Grundschober, Christian Klein, Ekkehard Moessner, Samuel Moser, Pablo Umana, Tina Weinzierl
  • Antibodies binding to STEAP-1
    Publication number: 20200190212
    Abstract: The present invention generally relates to antibodies that bind to STEAP-1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: September 30, 2019
    Publication date: June 18, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Thomas HOFER, Maximiliane KOENIG, Ekkehard MOESSNER, Jens NIEWOEHNER, Tina WEINZIERL, Laurent LARIVIERE
  • Monoclonal antibodies against BCMA
    Patent number: 10683369
    Abstract: The invention relates to new antibodies against BCMA, their manufacture and use.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: June 16, 2020
    Assignee: EngMab Sàrl
    Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Camille Delon, Lydia Jasmin Hanisch, Anne Freimoser-Grundschober, Christian Klein, Ekkehard Moessner, Samuel Moser, Pablo Umana, Tina Weinzierl
  • MONOCLONAL ANTIBODIES AGAINST BCMA
    Publication number: 20190352427
    Abstract: The invention relates to new antibodies against BCMA, their manufacture and use.
    Type: Application
    Filed: August 3, 2016
    Publication date: November 21, 2019
    Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Camille Delon, Lydia Jasmin Duerner, Anne Freimoser-Grundschober, Christian Klein, Ekkehard Moessner, Samuel Moser, Pablo Umana, Tina Weinzierl
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20190177413
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: February 22, 2019
    Publication date: June 13, 2019
    Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane JAEGER, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL